[HTML][HTML] The NUTRIENT trial (NUTRitional intervention among myEloproliferative Neoplasms): feasibility phase
LFM Luque, J Avelar-Barragan, H Nguyen, J Nguyen… - medRxiv, 2023 - ncbi.nlm.nih.gov
Purpose: Chronic inflammation is integral to Myeloproliferative Neoplasm (MPN)
pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects …
pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects …
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
LF Mendez Luque, J Avelar-Barragan, H Nguyen… - Cancer Research …, 2024 - AACR
Purpose: Chronic inflammation is integral to myeloproliferative neoplasm (MPN)
pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects …
pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects …
Non-pharmacologic approaches to target inflammation in Myeloproliferative Neoplasms
LF MENDEZ LUQUE - 2021 - escholarship.org
Myeloproliferative neoplasms (MPNs) are hematologic malignancies that result from a
somatic mutation, most commonly in the Janus kinase (JAK2V617F) causing the constitutive …
somatic mutation, most commonly in the Janus kinase (JAK2V617F) causing the constitutive …
[图书][B] Non-pharmacologic Approaches to Target Inflammation in Myeloproliferative Neoplasms
LFM Luque - 2021 - search.proquest.com
Myeloproliferative neoplasms (MPNs) are hematologic malignancies that result from a
somatic mutation, most commonly in the Janus kinase (JAK2 V617F) causing the constitutive …
somatic mutation, most commonly in the Janus kinase (JAK2 V617F) causing the constitutive …